Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Blood-based gene tests show promise for pancreatic cancer screening

Researchers at Kanazawa University report the blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.

16 Jul 2026

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

16 Jul 2026

HonorHealth offers new drug that doubles pancreatic cancer survival

Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation to offer a new drug, Daraxonrasib, that based on early data nearly doubles the average survival time of patients with pancreatic cancer.

7 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Japanese study links inherited genetic variants to multiple lung cancers

Lung cancer remains the leading cause of cancer-related deaths worldwide and is generally thought to arise from mutations acquired over a lifetime through environmental exposures.

30 Jun 2026

Scientists discover 70 existing drugs that block deadly hantavirus infections

Researchers screened over 5,000 compounds and successfully pinpointed 70 existing drugs, including unexpected beta-lactam antibiotics, that effectively suppress Puumala orthohantavirus infection in human cells. This milestone drug-repurposing study provides an immediate, fast-tracked pipeline for developing the first approved treatments against life-threatening hantavirus diseases.

28 Jun 2026

Lactate and lactylation play multifaceted roles in pancreatic ductal adenocarcinoma

A comprehensive review recently published in Current Molecular Pharmacology illuminates the pivotal, multifaceted roles of lactate and its downstream protein modification, lactylation, in pancreatic ductal adenocarcinoma (PDAC).

25 Jun 2026

Targeting metabolic pathways could prevent relapse in KRAS-mutant cancers

Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous.

25 Jun 2026

Microbes trigger cell death to boost cancer immunotherapy effectiveness

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

24 Jun 2026

New CellTrap technology reveals how single immune cells attack brain tumors

Established laboratory tests mainly capture average values across many cells and show, for example, how many cancer cells survive after contact with immune cells.

18 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

15 Jun 2026

New genetic driver found for rare small intestinal cancers

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide, and renew themselves.

12 Jun 2026

Study identifies new therapeutic candidate for KRAS-driven pancreatic cancer

A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation."

8 Jun 2026

Amplified Sciences secures investment for pancreatic cyst diagnostic assay

Amplified Sciences, a clinical-stage diagnostics company pioneering next-generation multi-omic assays, today announced a new investment from the American Gastroenterological Association's (AGA) GI Opportunity Fund as part of its recent Seed+ financing round.

4 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Degrading mutant KRAS protein induces greater lung cancer regression

KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas.

27 May 2026

Lung cancer cells change identity to resist medical treatments

Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment.

27 May 2026

Ferroptosis exploits unique cancer metabolic vulnerabilities to bypass traditional apoptotic evasion pathways

A new wave of scientific understanding is placing ferroptosis, a distinct form of iron-dependent cell death, at the forefront of efforts to overcome drug resistance in digestive cancers. These cancers, which include gastric, colorectal, liver, pancreatic, and esophageal malignancies, remain among the most challenging to treat due to their ability to evade standard therapies.

25 May 2026